A 28 day, polysomnographic and subjective assessment of GW679769 [casopitant] for the treatment of primary insomnia: a randomized, double-blind, parallel-group, placebo-controlled trial
Phase of Trial: Phase II
Latest Information Update: 22 Apr 2015
At a glance
- Drugs Casopitant (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 07 Dec 2007 Status changed from in progress to completed.
- 27 Jan 2007 Status change
- 24 Oct 2006 New trial record.